Steve Ubl, who leads the drug industry lobbying powerhouse PhRMA, has a bold prediction: Democrats might control the House, Senate, and White House, but Covid-19 has given pharma the advantage in the debate over drug pricing.
Trending:
PhRMA chief talks strategy — and he's surprisingly optimistic about drug pricing reform